Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seniprutug in Active Axial Spondyloarthritis
NCT06333210Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of seniprutug in axial spondyloarthritis (axSpA) (5 arms), sponsored by BIOCAD. Primary endpoints: Proportion of subjects who achieved ASAS40 among bDMARDs and tsDMARD-naive subjects at 24 weeks and Proportion of subjects who achieved ASAS40 among bDMARDs and/or tsDMARD-experienced subjects at 24 weeks. Started Dec 2023; status: active, not recruiting.
02
Drugs
seniprutug
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT06333210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333210.